Inventiva (IVA) Reports Q2 Loss of EUR0.60
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Inventiva reports 2021 first half financial results and provides a corporate update
September 20, 2021 4:10 PM EDTÂ
Cash and cash equivalents at 93.6 m as of June 30, 2021 compared to 105.7 m1 as of December 31, 2020 Initiation of the NATiV3 Phase III clinical study with lanifibranor in NASH R&D expenses of 19.1 m in H1 2021, up 52% compared to H1 2020, mainly driven by the preparation and initiation of the NATiV3 Phase III clinical trial Decision by AbbVie to initiate a Phase IIb clinical trial with cedirogant in patients with moderate to severe psoriasis following the demonstration of clinical proof of concept during AbbVies Phase Ib clinical trial ... More